Europe Pharmaceutical Contract Development and Manufacturing Organization Market
Europe pharmaceutical CDMO market accounted for $37.17 billion in 2019 and will grow by 6.7% annu ... Read More
Table of Contents 1 Introduction 7 1.1 Industry Definition and Research Scope 7 1.1.1 Industry Definition 7 1.1.2 Research Scope 8 1.2 Research Methodology 11 1.2.1 Overview of Market Research Methodology 11 1.2.2 Market Assumption 12 1.2.3 Secondary Data 12 1.2.4 Primary Data 12 1.2.5 Data Filtration and Model Design 14 1.2.6 Market Size/Share Estimation 15 1.2.7 Research Limitations 16 1.3 Executive Summary 17 2 Market Overview and Dynamics 19 2.1 Market Size and Forecast 19 2.1.1 Impact of COVID-19 on World Economy 20 2.1.2 Impact of COVID-19 on the Market 23 2.2 Major Growth Drivers 25 2.3 Market Restraints and Challenges 30 2.4 Emerging Opportunities and Market Trends 33 2.5 Porter’s Fiver Forces Analysis 37 3 Segmentation of North America Market by Category 41 3.1 Market Overview by Category 41 3.2 Pharmaceutical Industry 43 3.3 Biopharmaceutical Industry 44 4 Segmentation of North America Market by Service Type 45 4.1 Market Overview by Service Type 45 4.2 Pharmaceutical Contract Manufacturing Organization (CMO) 47 4.2.1 Active Pharmaceutical Ingredients (API) 48 4.2.2 Finished Dosage Formulations (FDF) 49 4.2.3 Secondary Packaging 51 4.3 Pharmaceutical Contract Research Organization (CRO) 52 4.3.1 CRO for Pre-clinical Development 54 4.3.2 CRO for Phase I Trials 55 4.3.3 CRO for Phase II Trials 56 4.3.4 CRO for Phase III Trials 57 4.3.5 CRO for Phase IV Trials 58 4.3.6 Laboratory Services 59 4.3.7 Consulting Services 60 4.3.8 Data Management Services 61 5 Segmentation of North America Market by Therapeutic Application 62 5.1 Market Overview by Therapeutic Application 62 5.2 Infectious Diseases 64 5.3 Oncology 65 5.4 Metabolic Disorders 66 5.5 Cardiovascular Disorders 67 5.6 Central Nervous System 68 5.7 Pulmonary Disorders 69 5.8 Gastrointestinal Disorders 70 5.9 Other Therapeutic Applications 71 6 Segmentation of North America Market by End User 72 6.1 Market Overview by End User 72 6.2 Pharmaceutical & Biopharmaceutical Companies 74 6.3 Medical Device Companies 75 6.4 Academic Institutes 76 7 North America Market 2019-2030 by Country 77 7.1 Overview of North America Market 77 7.2 U.S. 80 7.3 Canada 84 7.4 Mexico 86 8 Competitive Landscape 88 8.1 Overview of Key Vendors 88 8.2 New Product Launch, Partnership, Investment, and M&A 92 8.3 Company Profiles 93 8.3.1 Company Profiles of CMO 93 Aenova Group 93 Baxter BioPharma Solutions 96 Boehringer Ingelheim 97 Catalent Inc. 98 Famar S.A. 99 Hospira, Inc. 100 Jubilant Life Sciences Ltd. 101 Lonza Group 102 Patheon Inc. 103 Pfizer CentreSource 104 Recipharm AB 105 Vetter Pharma International GmbH 106 8.3.2 Company Profiles of CRO 108 Charles River Laboratories 108 CMIC Co. Ltd 110 Covance Inc. 111 Hangzhou Tigermed Consulting Co Ltd 112 ICON Plc 113 IQVIA Holdings Inc. 114 LSK North America Pharma Service Co Ltd 115 Novotech Pty Ltd 116 PAREXEL International Corporation 117 Pharmaceutical Product Development LLC (PPD) 118 PRA Health Sciences Inc. 119 Quanticate Ltd 120 Samsung Bioepis Co. Ltd 121 SGS SA (SGS Life Sciences) 122 Syneos Health Inc. 123 WuXi AppTec Inc. 124 9 Investing in North America Market: Risk Assessment and Management 125 9.1 Risk Evaluation of North America Market 125 9.2 Critical Success Factors (CSFs) 128 Related Reports and Products 131
Table 1. Snapshot of North America Pharmaceutical CDMO Market in Balanced Perspective, 2019-2030 18 Table 2. Growth Rate of World Real GDP, 2017-2021 21 Table 3. World Top 10 Pharmaceutical Companies Based on Projected R&D Spending in 2026, $ bn 27 Table 4. Worldwide Total Number of Registered Clinical Trials 29 Table 5. Main Product Trends and Market Opportunities in North America Pharmaceutical CDMO Market 33 Table 6. North America Pharmaceutical CDMO Market by Category, 2019-2030, $ bn 41 Table 7. North America Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn 45 Table 8. North America Pharmaceutical CDMO Market: CMO by Product, 2019-2030, $ bn 47 Table 9. North America Pharmaceutical CDMO Market: Active Pharmaceutical Ingredients (API) by Type, 2019-2030, $ bn 48 Table 10. North America Pharmaceutical CDMO Market: Finished Dosage Formulations (FDF) by Type, 2019-2030, $ bn 50 Table 11. North America Pharmaceutical CDMO Market: CRO by Service, 2019-2030, $ bn 53 Table 12. North America Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn 62 Table 13. North America Pharmaceutical CDMO Market by End User, 2019-2030, $ bn 72 Table 14. North America Pharmaceutical CDMO Market by Country, 2019-2030, $ bn 78 Table 15. U.S. Pharmaceutical CDMO Market by Category, 2019-2030, $ bn 82 Table 16. U.S. Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn 82 Table 17. U.S. Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn 82 Table 18. Canada Pharmaceutical CDMO Market by Category, 2019-2030, $ bn 85 Table 19. Canada Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn 85 Table 20. Canada Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn 85 Table 21. Mexico Pharmaceutical CDMO Market by Category, 2019-2030, $ bn 87 Table 22. Mexico Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn 87 Table 23. Mexico Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn 87 Table 24. Breakdown of North America CMO Market by Key Vendor, 2019, % 90 Table 25. Breakdown of North America CRO Market by Key Vendor, 2019, % 90 Table 26. Aenova Group: Company Snapshot 93 Table 27. Aenova Group: Business Segmentation 93 Table 28. Aenova Group: Product Portfolio 95 Table 29. Aenova Group: Revenue, 2016-2018, $ bn 95 Table 30. Aenova Group: Recent Developments 95 Table 31. Charles River Laboratories: Company Snapshot 108 Table 32. Charles River Laboratories: Business Segmentation 108 Table 33. Charles River Laboratories: Product Portfolio 109 Table 34. Charles River Laboratories: Revenue, 2016-2018, $ bn 109 Table 35. Charles River Laboratories: Recent Developments 109 Table 36. Risk Evaluation for Investing in North America Market, 2019-2030 126 Table 37. Critical Success Factors and Key Takeaways 129
Figure 1. Research Method Flow Chart 11 Figure 2. Breakdown of Primary Research 13 Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15 Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 17 Figure 5. North America Pharmaceutical CDMO Market, 2019-2030, $ bn 19 Figure 6. Impact of COVID-19 on Business 23 Figure 7. Primary Drivers and Impact Factors of North America Pharmaceutical CDMO Market 25 Figure 8. Primary Restraints and Impact Factors of North America Pharmaceutical CDMO Market 30 Figure 9. Investment Opportunity Analysis 34 Figure 10. Porter’s Fiver Forces Analysis of North America Pharmaceutical CDMO Market 37 Figure 11. Breakdown of North America Pharmaceutical CDMO Market by Category, 2019-2030, % of Revenue 41 Figure 12. North America Addressable Market Cap in 2020-2030 by Category, Value ($ bn) and Share (%) 42 Figure 13. North America Pharmaceutical CDMO Market: Pharmaceutical Industry, 2019-2030, $ bn 43 Figure 14. North America Pharmaceutical CDMO Market: Biopharmaceutical Industry, 2019-2030, $ bn 44 Figure 15. Breakdown of North America Pharmaceutical CDMO Market by Service Type, 2019-2030, % of Sales Revenue 45 Figure 16. North America Addressable Market Cap in 2020-2030 by Service Type, Value ($ bn) and Share (%) 46 Figure 17. North America Pharmaceutical CDMO Market: Pharmaceutical Contract Manufacturing Organization (CMO), 2019-2030, $ bn 47 Figure 18. North America Pharmaceutical CDMO Market: Active Pharmaceutical Ingredients (API), 2019-2030, $ bn 48 Figure 19. North America Pharmaceutical CDMO Market: Finished Dosage Formulations (FDF), 2019-2030, $ bn 49 Figure 20. North America Pharmaceutical CDMO Market: Secondary Packaging, 2019-2030, $ bn 51 Figure 21. North America Pharmaceutical CDMO Market: Pharmaceutical Contract Research Organization (CRO), 2019-2030, $ bn 52 Figure 22. North America Pharmaceutical CDMO Market: CRO for Pre-clinical Development, 2019-2030, $ bn 54 Figure 23. North America Pharmaceutical CDMO Market: CRO for Phase I Trials, 2019-2030, $ bn 55 Figure 24. North America Pharmaceutical CDMO Market: CRO for Phase II Trials, 2019-2030, $ bn 56 Figure 25. North America Pharmaceutical CDMO Market: CRO for Phase III Trials, 2019-2030, $ bn 57 Figure 26. North America Pharmaceutical CDMO Market: CRO for Phase IV Trials, 2019-2030, $ bn 58 Figure 27. North America Pharmaceutical CDMO Market: Laboratory Services, 2019-2030, $ bn 59 Figure 28. North America Pharmaceutical CDMO Market: Consulting Services, 2019-2030, $ bn 60 Figure 29. North America Pharmaceutical CDMO Market: Data Management Services, 2019-2030, $ bn 61 Figure 30. Breakdown of North America Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, % of Sales Revenue 63 Figure 31. North America Addressable Market Cap in 2020-2030 by Therapeutic Application, Value ($ bn) and Share (%) 63 Figure 32. North America Pharmaceutical CDMO Market: Infectious Diseases, 2019-2030, $ bn 64 Figure 33. North America Pharmaceutical CDMO Market: Oncology, 2019-2030, $ bn 65 Figure 34. North America Pharmaceutical CDMO Market: Metabolic Disorders, 2019-2030, $ bn 66 Figure 35. North America Pharmaceutical CDMO Market: Cardiovascular Disorders, 2019-2030, $ bn 67 Figure 36. North America Pharmaceutical CDMO Market: Central Nervous System, 2019-2030, $ bn 68 Figure 37. North America Pharmaceutical CDMO Market: Pulmonary Disorders, 2019-2030, $ bn 69 Figure 38. North America Pharmaceutical CDMO Market: Gastrointestinal Disorders, 2019-2030, $ bn 70 Figure 39. North America Pharmaceutical CDMO Market: Other Therapeutic Applications, 2019-2030, $ bn 71 Figure 40. Breakdown of North America Pharmaceutical CDMO Market by End User, 2019-2030, % of Revenue 72 Figure 41. North America Addressable Market Cap in 2020-2030 by End User, Value ($ bn) and Share (%) 73 Figure 42. North America Pharmaceutical CDMO Market: Pharmaceutical & Biopharmaceutical Companies, 2019-2030, $ bn 74 Figure 43. North America Pharmaceutical CDMO Market: Medical Device Companies, 2019-2030, $ bn 75 Figure 44. North America Pharmaceutical CDMO Market: Academic Institutes, 2019-2030, $ bn 76 Figure 45. Breakdown of North America Pharmaceutical CDMO Market by Country, 2019 and 2030, % of Revenue 78 Figure 46. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%) 79 Figure 47. U.S. Pharmaceutical CDMO Market, 2019-2030, $ bn 81 Figure 48. Canada Pharmaceutical CDMO Market, 2019-2030, $ bn 84 Figure 49. Pharmaceutical CDMO Market in Mexico, 2015-2030, $ bn 86 Figure 50. Growth Stage of North America Pharmaceutical CDMO Industry over the Forecast Period 88
Key Players (this may not be a complete list and extra companies can be added upon request): Company Profiles of CMO: Aenova Group Baxter BioPharma Solutions Boehringer Ingelheim Catalent Inc. Famar S.A. Hospira, Inc. Jubilant Life Sciences Ltd. Lonza Group Patheon Inc. Pfizer CentreSource Recipharm AB Vetter Pharma International GmbH 8.3.2 Company Profiles of CRO: Charles River Laboratories CMIC Co. Ltd Covance Inc. Hangzhou Tigermed Consulting Co Ltd ICON Plc IQVIA Holdings Inc. LSK Global Pharma Service Co Ltd Novotech Pty Ltd PAREXEL International Corporation Pharmaceutical Product Development LLC (PPD) PRA Health Sciences Inc. Quanticate Ltd Samsung Bioepis Co. Ltd SGS SA (SGS Life Sciences) Syneos Health Inc. WuXi AppTec Inc.
Europe pharmaceutical CDMO market accounted for $37.17 billion in 2019 and will grow by 6.7% annu ... Read More
Asia Pacific pharmaceutical CDMO market will grow by 8.3% annually with a total addressable marke ... Read More
Global pharmaceutical CRO market will reach $104.4 billion by 2030, growing by 8.1% annually over ... Read More
North America pharmaceutical CRO market is expected to grow by 7.3% annually in the forecast peri ... Read More